Streetbeat News

Products Services

GIB

CGI (NYSE:GIB) has entered into a 10-year strategic partnership with Posti Group to develop and deliver digital multichannel messaging services. The partnership includes the transfer of 88 professionals from Finland, Poland, Latvia, and Estonia to CGI, and a collaboration to modernize digital messaging technology. This will enable Posti to better meet customer expectations and enhance cybersecurity and operational security.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 10:02 am

BYDDF

BYDDY

Chinese EV maker BYD Co Ltd, backed by Warren Buffett's Berkshire Hathaway, forecasts a minimum 74.5% increase in net profit for FY23, attributing the rise to higher sales volumes. BYD surpassed Tesla in Q4 as the largest BEV seller, moving 526,000 units compared to Tesla's 485,000. The company's expected net profit is between 29,000 million yuan and 31,000 million yuan, with a basic EPS of 9.98 to 10.67 yuan, up from 5.71 yuan in FY22.

Portfolio Pulse from Anan Ashraf

January 30, 2024 | 9:54 am

RNLSY

RNSDF

Renault Group has postponed the IPO of its EV and software arm Ampere due to unfavorable stock market conditions. Initially planned for the first half of 2024, Renault now aims to fund Ampere until it reaches breakeven in 2025. The decision follows Renault's ability to generate sustainable cash flow, as demonstrated by its 2023 results. Ampere will concentrate on reducing EV costs and launching new vehicles.

Portfolio Pulse from Anan Ashraf

January 30, 2024 | 9:15 am

CHT

Chunghwa Telecom Co. anticipates a revenue increase of 2.4%-3.1% YoY for 2024, with expected revenues between NT$228.54B and NT$230.19B. The company projects an EPS of NT$4.60-NT$4.80. Operating costs are also expected to rise by 4.0%-4.6%, leading to a potential decrease in income from operations. Investments in 5G, data centers, submarine cables, and ESG practices are driving an increase in property, plant, and equipment acquisitions.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 9:12 am

SHIBUSD

Shiba Inu (CRYPTO: SHIB) experienced a significant increase in token burns, with a 1,500% rise in a single day. This surge is linked to the upcoming integration of 1,000 new projects into Shibarium, their Layer-2 solution. Shibarium currently supports NFTs, DEXs, and dApps, and has a TVL of $808,810. The burn was executed by three entities sending 59 million SHIB to a 'dead' address, effectively removing them from circulation.

Portfolio Pulse from Mehab Qureshi

January 30, 2024 | 8:57 am

MOR

MorphoSys AG (NASDAQ:MOR) reported preliminary 2023 Monjuvi U.S. net product sales of $92.0M and Q4 sales of $24.1M. The company expects 2024 sales to be between $80M-$95M, consistent with its original 2023 guidance. Growth is anticipated from new indications being studied in Phase 3 trials. The 2023 gross margin for Monjuvi is 69%, affected by one-time inventory write-offs. Full financial results will be released on March 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 8:23 am

SPGI

S&P Dow Jones Indices (S&P DJI) has been chosen by PenSam, a Danish pension provider, to create a custom climate-focused index using S&P DJI's beS&P Index service. This service allows clients to collaborate on index-based solutions tailored to their specific needs, incorporating proprietary exclusions and targeted exposures.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 8:09 am

CSCO

MSFT

SSNLF

At Integrated Systems Europe (ISE) 2024, Cisco, Microsoft, and Samsung announced new meeting room solutions for enhanced hybrid meetings. The collaboration includes Cisco Room Series integration with Microsoft Teams Rooms' Front Row layout and Samsung's Smart Signage screens.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 8:07 am

TPST

Tempest Therapeutics has announced significant progress in liver cancer treatment, presenting promising efficacy and safety data at the ASCO Annual Meeting 2024. This breakthrough could potentially improve treatment options for liver cancer patients.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 7:23 am

HCM

HUTCHMED has received approval for ELUNATE, an oral targeted therapy for metastatic colorectal cancer, in Hong Kong. This marks the first medicine approved under the new '1+' mechanism by the HKSAR Government. ELUNATE is the first such therapy approved in Hong Kong in nearly a decade and is already approved in mainland China, Macau SAR, and the United States.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 7:20 am